HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

FTRE

Fortrea Holdings Inc. (NASDAQ)

Healthcare — Biotechnology

Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical pharmacology, such as clinical research units, external partnerships, project management, study design and monitoring, bioanalytics and biomarkers, pharmacokinetics, modeling and simulation, and biometrics; and clinical development, including phase I through IV clinical and real-world evidence studies, regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, comprehensive site and medical monitoring, data management and biostatistics, pharmacovigilance, medical writing, and mobile clinical services. The company also provides consulting services comprising product development and regulatory, market access and health economics, and outcomes research, as well as RWE services. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.

Buy 2.3 / 5 11 analysts
$17.58
+$0.18 (+1.03%)
Target: $16.39 (-6.8%)
Sign in to add FTRE to a watchlist or set price alerts.

Price History

52-Week Range

Fundamentals

Market Cap$1.66B
P/E Ratio (TTM)-
Forward P/E16.33
EPS (TTM)$-4.81
Dividend Yield-
Profit Margin-16.50%
Revenue Growth-2.30%
ROE-64.55%
Debt/Equity212.70
Recommendation Buy 2.3
Analyst Target$16.39
Analysts11
Indexes NASDAQ

Technical Indicators

RSI (14)61.7
Beta2.11
SMA 20-
SMA 40-
52-Week High$18.67
52-Week Low$4.36
50-Day Avg$14.58
200-Day Avg$12.72
Avg Volume$1.43M
Volume$1.51M

Performance Analysis

NEUTRAL

FTRE presents a mixed picture with both positive and negative indicators.

- Trading near its 52-week high ($18.67), which may indicate limited upside.
+ RSI at 61.7 shows positive momentum.
+ Price is above both the 50-day and 200-day moving averages — strong uptrend.
- Revenue declined 2.3% year-over-year.
- Operating at a loss with -16.5% margin.
+ Wall Street consensus is "Buy" from 11 analysts.
- Average analyst target of $16.39 implies 6.8% downside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 02, 2026 13:10 UTC

Back to Screener Export Report